BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 25150165)

  • 41. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
    Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
    Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.
    Bird T; Barrington S; Thavaraj S; Jeannon JP; Lyons A; Oakley R; Simo R; Lei M; Guerrero Urbano T
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1239-47. PubMed ID: 26707387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma.
    Nishimura G; Yabuki K; Hata M; Komatsu M; Taguchi T; Takahashi M; Shiono O; Sano D; Arai Y; Takahashi H; Chiba Y; Oridate N
    Int J Clin Oncol; 2016 Aug; 21(4):658-667. PubMed ID: 26710795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
    Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
    Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
    Dejaco D; Uprimny C; Widmann G; Riedl D; Moser P; Arnold C; Steinbichler TB; Kofler B; Schartinger VH; Virgolini I; Riechelmann H
    Cancer Imaging; 2020 Sep; 20(1):69. PubMed ID: 32993805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
    Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI.
    Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: An institutional experience.
    Wotman M; Ghaly M; Massaro L; Tham T; Seetharamu N; Kamdar D; Frank D; Kraus D; Teckie S
    Am J Otolaryngol; 2019; 40(5):684-690. PubMed ID: 31229365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N2 disease in patients with head and neck squamous cell cancer treated with chemoradiotherapy: is there a role for posttreatment neck dissection?
    Cho AH; Shah S; Ampil F; Bhartur S; Nathan CO
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1112-8. PubMed ID: 19917924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review.
    Taghipour M; Sheikhbahaei S; Marashdeh W; Solnes L; Kiess A; Subramaniam RM
    JAMA Otolaryngol Head Neck Surg; 2016 Jan; 142(1):79-85. PubMed ID: 26583955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma].
    Haenggeli CA; Dulguerov P; Slosman D; Becker M; Bang P; Allal A; Guyot JP; Lehmann W
    Schweiz Med Wochenschr Suppl; 2000; 116():8S-11S. PubMed ID: 10780061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI.
    Stuckensen T; Kovács AF; Adams S; Baum RP
    J Craniomaxillofac Surg; 2000 Dec; 28(6):319-24. PubMed ID: 11465137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between extracapsular spread and FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Joo YH; Yoo IeR; Cho KJ; Park JO; Nam IC; Kim CS; Kim MS
    Acta Otolaryngol; 2013 Oct; 133(10):1073-9. PubMed ID: 24032571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer.
    Gourin CG; Williams HT; Seabolt WN; Herdman AV; Howington JW; Terris DJ
    Laryngoscope; 2006 May; 116(5):705-10. PubMed ID: 16652075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using
    Noij DP; Jagesar VA; de Graaf P; de Jong MC; Hoekstra OS; de Bree R; Castelijns JA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):296-305.e2. PubMed ID: 28539202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all?
    Pellitteri PK; Ferlito A; Rinaldo A; Shah JP; Weber RS; Lowry J; Medina JE; Gourin CG; Robbins KT; Suárez C; Shaha AR; Genden EM; Leemans CR; Lefebvre JL; Kowalski LP; Wei WI
    Head Neck; 2006 Feb; 28(2):166-75. PubMed ID: 16240327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy.
    Liu HY; Milne R; Lock G; Panizza BJ; Bernard A; Foote M; McGrath M; Brown E; Gandhi M; Porceddu SV
    Oral Oncol; 2019 Jan; 88():153-159. PubMed ID: 30616786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.